The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | An update on MDS diagnosis and management
In this video, Dominiek Mazure, MD, Ghent University Hospital, Ghent, Belgium, discusses the key points from a talk at the EBMT 2025 meeting in which she gave an update on the diagnosis and management of myelodysplastic syndrome (MDS). Dr Mazure highlights the importance of cytogenetics and somatic mutations in the diagnosis, classification, and prognostication of the disease. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I indeed discussed the myelodysplastic neoplasms. There are not a lot of new things. I discussed the diagnosis which is dependent on cytopenias, but the definition for cytopenias has changed as now the criteria apply to the cytopenias as defined by the WHO. Furthermore, you have to do a bone marrow biopsy and aspirate to demonstrate the dysplasia. And of course we have all the new information on cytogenetics and somatic mutations and these are very important in the diagnosis and improvement of clonal hematopoiesis, which is one of the concepts of MDS...
I indeed discussed the myelodysplastic neoplasms. There are not a lot of new things. I discussed the diagnosis which is dependent on cytopenias, but the definition for cytopenias has changed as now the criteria apply to the cytopenias as defined by the WHO. Furthermore, you have to do a bone marrow biopsy and aspirate to demonstrate the dysplasia. And of course we have all the new information on cytogenetics and somatic mutations and these are very important in the diagnosis and improvement of clonal hematopoiesis, which is one of the concepts of MDS. Furthermore, we use it to classify the MDS. Certain specific mutations classify MDS as MDS with deletion 5q or with the SF3B1 mutation, and of course, it’s used in prognosis. Furthermore, I discussed the therapy but unfortunately in therapy there have not been a lot of new changes. We are awaiting new treatments or associations with azacitidine in non-transplant eligible patients but furthermore there are not a lot of new treatment options in the last few years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Lecture fees and consultancy fees: Novartis, Incyte, BMS, GSK.
